摘要
目的探讨痰热清注射液治疗慢性阻塞性肺疾病急性加重(Acute exacerbation of chronic obstructive pulmonary disease,AECOPD)疗效,同时基于网络药理学及细胞实验验证其作用机制。方法选择80例AECOPD患者,随机分为对照组和联合组各40例;两组均给予西医常规治疗,联合组加用痰热清注射液治疗;比较两组中医临床疗效、炎性因子和安全性。利用TCMSP等数据库和Cytoscape 3.7.0等软件筛选出痰热清注射液治疗AECOPD的作用机制,并通过人支气管上皮细胞16HBE实验验证。结果联合组中医临床有效率显著高于对照组(P<0.05);两组WBC、hs-CRP、IL-6和SAA较治疗前均显著下降(P<0.05),且联合组显著低于对照组(P<0.05);两组不良反应比较无显著差异(P>0.05)。网络药理学筛选得到IL-6、MAPK1、AKT1等关键靶点,IL-17信号通路、PI3K-Akt信号通路等关键通路。与空白组比较,模型组细胞中MAPK1、IL-6、p-AKT/AKT、PI3K蛋白表达均显著增高(P<0.01);与模型组比较,痰热清注射液低、高剂量组MAPK1、IL-6、p-AKT、AKT、PI3K蛋白表达显著降低(P<0.05),且呈剂量依赖性。结论痰热清注射液可降低AECOPD患者炎症水平,提高中医临床疗效,其机制可能与抑制IL-6、PI3K、p-AKT/AKT等蛋白表达,调控PI3K-Akt信号通路相关。
Objective To explore the clinical efficacy and mechanism of Tanreqing injection on patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)based on network pharmacology and cell experiments.Methods The 80 patients with AECOPD were divided into a control group and a combination group of 40 cases according to the random number method.Both groups were given conventional Western medicine treatment,and the combined group was treated with Tanreqing injection.The clinical efficacy of TCM,inflammatory factors and safety were compared between the two groups of patients.Databases such as TCMSP and software such as Cytoscape 3.7.0 were used to screen out the mechanism of Tanreqing injection in the treatment of AECOPD,and human bronchial epithelial cells 16HBE were used for experimental verification.Results The clinical effective of TCM in the combined group was higher than that in the control group(P<0.05).WBC,hs-CRP,IL-6 and SAA in the two groups were lower than before treatment(P<0.05),and those of the combined group were lower than control group(P<0.05).There was no statistically difference in adverse reactions between the two groups(P>0.05).Key targets such as MAPK1,IL-6,AKT1,and key pathways such as IL-17 signaling pathway and PI3K-Akt signaling pathway were obtained by network pharmacology methods.The level of MAPK1,IL-6,p-AKT/AKT and PI3K in the model group were significantly lower than the blank group(P<0.01);Compared with the model group,the expression of MAPK1,IL-6,pAKT/AKT and PI3K protein in the Tanreqing extract group significantly and dose-dependently reduced(P<0.05).Conclusion Tanreqing injection can reduce the inflammation level and improve the clinical efficacy in AECOPD patients.Its mechanism may be related to the inhibition of protein expression including IL-6,PI3K and p-AKT/AKT,and the regulation of the PI3K-Akt signaling pathway.
作者
林云霞
朱珠
LIN Yunxia;ZHU Zhu(Chest Hospital Area of Nanjing Brain Hospital,Nanjing 210029,China)
出处
《世界科学技术-中医药现代化》
北大核心
2025年第5期1434-1446,共13页
Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金
江苏省卫生健康委员会2019年度科技项目(H2019040):痰热清注射液治疗COPD的物质基础及分子机制研究,负责人:林云霞。
关键词
慢性阻塞性肺疾病急性加重
痰热清注射液
临床疗效
网络药理学
细胞实验
Acute exacerbation of chronic obstructive pulmonary disease
Tanreqing injection
Clinical efficacy
Network pharmacology
Cell experiment
